The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.

Other Programs Supported by The Life Raft Group:

Real World Evidence In Action

Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to GIST research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.

RECENT LRG DATA

0
Patients in LRG Registry
0%
of Patient Registry members know their mutation
0
Total # of Tissue
0%
of LRG members know their Risk of Recurrence

Update your Patient Registry Info.

Join The Life Raft Group.

Current GIST Clinical Trials.

Search the GIST Specialist Database.

Dr. Monica Anderson

Dr. Monica Anderson

Diagnosed in 2012 with Adult GIST.

Bella Rocco

Bella Rocco

Diagnosed in 2009 with Pediatric
(SDH-deficient) GIST.

HELP US SAVE LIVES

The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.

Upcoming Events

GIST Day of Learning Vancouver

GIST Day of Learning Vancouver

October 17 @ 9:30 AM - 4:00 PM

GDOL San Diego

GDOL San Diego

October 24

News

Your GISTory and Why it is Important!

By |June 26th, 2013|

Having your GISTory or medical summary up to date and handy when faced with a medical emergency, is crucial to have on hand, when making decisions on how to proceed with your care.

  • corless figure 1

How ‘Next Generation’ DNA sequencing is changing the landscape of GIST research and diagnosis

By |June 11th, 2013|

During the past dozen years gastrointestinal stromal tumors have emerged from oncologic obscurity and reached center-stage in the development of targeted therapies for solid tumors. Tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and more recently regorafenib, have proven effective in suppressing the growth of metastatic GIST, allowing patients to live far longer than during the previous era of ineffective chemotherapy.

  • GDOL Chicago

First GDOL Chicago hits a homerun!

By |June 11th, 2013|

Our first Chicago GIST Day of Learning (GDOL) was a huge success! Over 50 GISTers and their families gathered for a great day of learning, and sharing experiences. It was wonderful to get to meet so many new people and reconnect with old friends.

Keep up with the latest news, events, and opportunities to help.

To contact The Life Raft Group, please call 973-837-9092

PARTNERS & AFFILIATIONS